AstraZeneca (LON:AZN) Share Price Crosses Above 200 Day Moving Average – What’s Next?

AstraZeneca PLC (LON:AZN) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of £112.23 ($144.78) and traded as high as £115.52 ($149.02). AstraZeneca shares last traded at £113.92 ($146.96), with a volume of 1,971,750 shares.

Analyst Upgrades and Downgrades

AZN has been the topic of a number of research analyst reports. JPMorgan Chase & Co. restated an “overweight” rating on shares of AstraZeneca in a report on Wednesday, February 19th. Shore Capital restated a “buy” rating on shares of AstraZeneca in a report on Friday, March 7th. Finally, Berenberg Bank reiterated a “buy” rating and issued a GBX 140 ($1.81) price target on shares of AstraZeneca in a report on Wednesday, March 26th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, AstraZeneca currently has an average rating of “Moderate Buy” and a consensus target price of GBX 7,542.80 ($97.30).

AstraZeneca Stock Down 3.0 %

The company has a market capitalization of £212.69 billion, a P/E ratio of 30.30, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. The company has a 50-day moving average of £116.11 and a two-hundred day moving average of £112.22. The company has a quick ratio of 0.59, a current ratio of 0.93 and a debt-to-equity ratio of 73.83.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.